烟酰胺核糖对肥胖非糖尿病男性内分泌胰腺功能及肠促胰素的影响
这项12周随机双盲安慰剂对照平行组试验在40例肥胖伴胰岛素抵抗男性中评估烟酰胺核糖(NR)1000 mg每日两次对β细胞功能、α细胞功能、肠促胰素及胆汁酸的影响。结果显示NR补充未改变空腹或糖负荷后血糖、胰岛素、C肽、胰高血糖素、GLP-1或GIP浓度,β细胞功能无响应,循环adipsin或胆汁酸亦无变化。研究不支持NR补充改善该人群糖耐量、β细胞分泌能力、α细胞功能或肠促胰素分泌。
要点
- 12周NR 1000 mg每日两次未改善肥胖非糖尿病男性的β细胞功能。
- NR未影响空腹或糖负荷后GLP-1、GIP等肠促胰素及胰高血糖素水平。
- NR补充未改变循环adipsin或胆汁酸浓度。
核心结论
- 本研究不支持NAD+前体NR补充影响肥胖非糖尿病男性的糖耐量、β细胞分泌能力、α细胞功能及肠促胰素分泌。
- NR补充后血浆胆汁酸水平未发生变化。
研究设计与样本
- 12周随机、双盲、安慰剂对照、平行组试验,纳入40例肥胖伴胰岛素抵抗男性。
- 受试者分配至NR 1000 mg每日两次组(n=20)或安慰剂组(n=20)。
- 干预前后行2小时75-g口服葡萄糖耐量试验,测定血糖、胰岛素、C肽、胰高血糖素、GLP-1及GIP浓度。
- 基于血糖、胰岛素和C肽计算β细胞功能指数,并测定空腹血浆胆汁酸浓度。
主要发现
- 12周NR补充未影响空腹或糖负荷后血糖、胰岛素、C肽、胰高血糖素、GLP-1或GIP浓度。
- β细胞功能未对NR干预产生响应。
- NR补充后循环adipsin或胆汁酸未见变化。
临床怎么用
- 对于肥胖伴胰岛素抵抗的非糖尿病男性,不应期望通过NR补充改善β细胞功能或肠促胰素分泌。
局限性
- 研究仅纳入肥胖伴胰岛素抵抗的非糖尿病男性,结果不能外推至其他人群。
- 干预周期为12周,长期效果未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Augmenting nicotinamide adenine dinucleotide (NAD+) metabolism through dietary provision of NAD+ precursor vitamins translates to improved glucose handling in rodent models of obesity and diabetes. Preclinical evidence suggests that the NAD+/SIRT1 axis may be implicated in modulating important gut-related aspects of glucose regulation. We sought to test whether NAD+ precursor supplementation with nicotinamide riboside (NR) affects β-cell function, α-cell function, and incretin hormone secretion as well as circulating bile acid levels in humans. DESIGN: A 12-week randomized, double-blind, placebo-controlled, parallel-group trial in 40 males with obesity and insulin resistance allocated to NR at 1000 mg twice daily (n = 20) or placebo (n = 20). Two-hour 75-g oral glucose tolerance tests were performed before and after the intervention, and plasma concentrations of glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were determined. β-Cell function indices were calculated based on glucose, insulin, and C-peptide measurements. Fasting plasma concentrations of bile acids were determined. RESULTS: NR supplementation during 12 weeks did not affect fasting or postglucose challenge concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. Additionally, no changes in circulating adipsin or bile acids were observed following NR supplementation. CONCLUSION: The current study does not provide evidence to support that dietary supplementation with the NAD+ precursor NR serves to impact glucose tolerance, β-cell secretory capacity, α-cell function, and incretin hormone secretion in nondiabetic males with obesity. Moreover, bile acid levels in plasma did not change in response to NR supplementation.
引用
- Dollerup OL, Trammell SAJ, Hartmann B, et al. Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity. J Clin Endocrinol Metab. 2019. PMID: 31390002. doi:10.1210/jc.2019-01081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。